IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: In another study, IL‐1β and IL‐6 activation of CaSR in the parathyroid gland and the kidneys resulted in hypocalcemia, hypovitaminosis, and hypoparathyroidism, depicting the interaction between cytokines and mediators of vitamin D.50In chronic myeloid leukemia (CML) patients, Imatinib therapy inhibited IL‐6 levels and a resultant alteration in extracellular calcium.51